Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02303626 · ClinicalTrials.gov registry record · Phase 2
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
A Phase 2 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT02303626 is a Phase 2 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 110 participants.
The verdict
NCT02303626, a Phase 2 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of an oral treatment, BCX4161, in preventing acute attacks in participants with hereditary angioedema (HAE). Eligible participants will be randomized to receive one of two doses of BCX4161 or placebo for 12 weeks. The study will compare the number of acute attacks in each treatment group, as well as a number of other clinical outcomes, and the safety and tolerability of each dose of BCX4161 compared to placebo.
Interventions
- DRUG Placebo
- DRUG BCX4161
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2014-12-17 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02303626
The ClinicalTrials.gov registry entry for NCT02303626 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02303626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02303626 about?
NCT02303626 is a clinical study titled "12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks". This study will evaluate the safety and efficacy of an oral treatment, BCX4161, in preventing acute attacks in participants with hereditary angioedema (HAE). Eligible participants will be randomized to receive one of two doses of BCX4161 or placebo for 12 weeks. The study will compare the number of ...
What is the current status of trial NCT02303626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2014-12-17. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02303626?
The interventions under investigation include: Placebo (DRUG), BCX4161 (DRUG).
Who is sponsoring clinical trial NCT02303626?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.